A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
NCT03989414 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 424
Last updated 2024-11-29
Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Conditions
Interventions
- DRUG
-
CC-92480
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Elotuzumab
Specified dose on specified days
- DRUG
-
Isatuximab
Specified dose on specified days
- DRUG
-
Specified dose on specified days
Sponsors & Collaborators
-
Celgene
lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-09-30
- Primary Completion
- 2026-11-30
- Completion
- 2026-11-30
- FDA Drug
- Yes
Countries
- United States
- Canada
- Czechia
- Denmark
- France
- Germany
- Greece
- Italy
- Spain
Study Locations
More Related Trials
-
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
NCT04855136 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07222761 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
NCT03314181 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
NCT05981209 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
NCT00378105 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
NCT02874742 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
NCT02951819 ·Status: COMPLETED ·Phase: PHASE2
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
NCT00378209 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT03848845 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma
NCT00813150 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
NCT03651128 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
NCT01083602 ·Status: COMPLETED ·Phase: PHASE2
-
Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
NCT05909826 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+
NCT06874530 ·Status: RECRUITING
-
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
NCT06577025 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NCT01297764 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT01485835 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
NCT02159365 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01478048 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT03746652 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma
NCT00352742 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
NCT00153933 ·Status: COMPLETED ·Phase: PHASE1
-
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
NCT01029054 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
NCT04009109 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2